Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression

• Published in: BMC cancer Vol. 12; no. 1; p. 370
• Main Authors: Liu, Junye, Yang, Le, Zhang, Jian, Zhang, Jing, Chen, Yongbin, Li, Kangchu, Li, Yurong, Li, Yan, Yao, Libo, Guo, Guozhen
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 27-08-2012; BioMed Central; BMC
• Subjects: Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Bcl-2; Biology; Cancer; Cancer therapies; Care and treatment; Cell culture; Cell differentiation; Cervical cancer; Chemosensitivity; Chemotherapy; Cisplatin; Cisplatin - pharmacology; Crystal structure; Dosage and administration; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes; Genetic aspects; HeLa Cells; Hospitals; Humans; Hypoxia; MicroRNA; MicroRNAs - genetics; MicroRNAs - metabolism; Mortality; NDRG2; Physiological aspects; Proteins; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors; Proto-Oncogene Proteins c-bcl-2 - biosynthesis; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Radiation therapy; Repressor proteins; RNA Interference; Tumor Suppressor Proteins - deficiency; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; China
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-12-370

NDRG2, a member of N-Myc downstream regulated gene family, plays some roles in cellular stress, cell differentiation and tumor suppression. We have found that NDRG2 expression in cervical cancer Hela cells increases significantly upon stimulation with cisplatin, the most popular chemotherapeutic agent currently used for the treatment of advanced cervical cancer. This interesting phenomenon drove us to evaluate the role of NDRG2 in chemosensitivity of Hela cells.
In the present study, RNA interference was employed to down-regulate NDRG2 expression in Hela cells. RT-PCR and Western blot were used to detect expression of NDRG2, Bcl-2 and Bax in cancer cells. Real-time PCR was applied to detect miR-15b and miR-16 expression levels. Drug sensitivity was determined with MTT assay. Cell cloning efficiency was evaluated by Colony-forming assay. Apoptotic cells were detected with annexin V staining and flow cytometry.
In vitro drug sensitivity assay revealed that suppression of NDRG2 could sensitize Hela cells to cisplatin. Down-regulation of NDRG2 didn't influence the colony-forming ability but promoted cisplatin-induced apoptosis of Hela cells. Inhibition of NDRG2 in Hela cells was accompanied by decreased Bcl-2 protein level. However, Bcl-2 mRNA level was not changed in Hela cells with down-regulation of NDRG2. Further study indicated that miR-15b and miR-16, two microRNAs targetting Bcl-2, were significantly up-regulated in NDRG2-suppressed Hela cells.
These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16.